Clinical trials: Low Dose
Intubation
Low Dose of Midazolam is Superior to Conventional Dose for Rapid Sequence Intubation in Emergency Department (ED)
Midazolam has been used in rapid sequence intubation for a long time, and the recommended dose is 0.1mg/kg. In some studies, however, the reduced dose has been used with the concern of hemodynamic instability.
- Trial name
- NCT00783731
- Testing
- Low dose midazolam
- Where
- 2 sites in South Korea
- Sponsor
- Seoul National University Hospital
Brain and Central Nervous System Tumors
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00005637
- Testing
- carmustine, temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chemotherapy-induced Nausea and Vomiting
Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents
Chemotherapy-induced nausea and vomiting continues to be a significant problem in children and adolescents. Standard antiemetic therapy, including a 5-HT3 antagonist, aprepitant, and a corticosteroid, achieves complete control in…
- Trial name
- OZONE-V (NCT05346731)
- Testing
- Ondansetron, Dexamethasone, Aprepitant
- Where
- Russia
- Volunteers
- 210 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Type 1 Diabetes
Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes
Type 1diabetes (T1D) is caused by autoimmune destruction of the pancreatic islet ß-cells, leading to an absolute deficiency in insulin.
- Trial name
- DIABIL-2 (NCT02411253)
- Testing
- rhIL-2
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 141 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Septic Shock
Initiation of Hydrocortisone for the Treatment of Septic Shock
The purpose of this study : 1）to determine whether hydrocortisone is effective in the treatment of septic shock and 2) to identify the role of timing of low dose hydrocortisone administration in septic shock patients.
- Trial name
- NCT02580240
- Testing
- Hydrocortisone, saline
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Northern Jiangsu People's Hospital
Childhood-onset Systemic Lupus Erythematosus, Lupus Nephritis (LN)
Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)
Childhood-onset systemic lupus erythematosus (cSLE) is a severe chronic autoimmune disease with a high burden of major-organ involvement.
- Trial name
- LIGHT (NCT07719140)
- Testing
- High-dose prednisone, Low-dose prednisone
- Where
- 8 sites in China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College Hospital
HIV Infections
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.
- Trial name
- NCT00054717
- Testing
- Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
- Where
- 117 sites in United States, Australia and 2 more
- Volunteers
- 630 people
- Sponsor
- Boehringer Ingelheim
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
This phase II trial studies how well low dose, reduced frequency nivolumab works in treating patients with cancer that cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site) to…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Trial name
- NCT07576725
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- Uganda
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Arteriosclerosis
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
RATIONALE: Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
- Trial name
- NCT00050817
- Testing
- clopidogrel (SR25990)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 15,603 people
- Sponsor
- Sanofi
Neurofibromatosis Type 1 (NF1)
Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
This clinical trial is conducted by one of 4 locations; University of British Columbia (Vancouver, CA), University of Utah (Salt Lake City, UT, USA), University of Cincinnati (Cincinnati, OH, USA), and University of Hamburg…
- Trial name
- VitDBoneNF1 (NCT01968590)
- Testing
- Cholecalciferol
- Where
- 3 sites in United States, Canada
- Volunteers
- 26 people
- Sponsor
- University of Utah
Type 1 Diabetes, New Onset
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with…
- Trial name
- WAVE T1D (NCT07061574)
- Testing
- Anti-thymocyte globulin (ATG), verapamil extended-release capsule, Adalimumab
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- City of Hope Medical Center
Schizophrenia
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
- Trial name
- NCT01760889
- Testing
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg)
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Shire
Breast Cancer Invasive, Early-stage Breast Cancer
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in…
- Conditions
- Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- BRE-04 (NCT04891068)
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois Chicago
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003089
- Testing
- amifostine trihydrate, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the side effects and best dose of bortezomib when given together with melphalan, and total-body irradiation before stem cell transplant and to see how well it works in treating patients with multiple…
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01936090
- Testing
- Bortezomib, Total-Body Irradiation, Melphalan
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Mayo Clinic
Malignant Glioma
Low Dose Naltrexone for Glioma Patients
To compare the effects of low dose naltrexone (LDN) versus placebo on quality of life in high grade glioma patients undergoing standard chemoradiation
- Trial name
- NCT01303835
- Testing
- LDN
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Katy Peters
Syndrome of Inappropriate ADH (SIADH) Secretion, Hyponatremia
Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
The study is designed to assess the efficacy of an investigational drug called SR121463B (vasopressin receptor antagonist) in the treatment of low levels of sodium in the blood associated with the Syndrome of Inappropriate…
- Trial name
- NCT00032734
- Testing
- satavaptan (SR121463B)
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 35 people
- Sponsor
- Sanofi
Contrast Media, Computed Tomography
Multiple Arterial Phase Computed Tomography Examination to Improve Detection of Tumors in the Liver and Pancreas
To examine inter-subject variations of optimal late arterial phase contrast-enhancement defined as the greatest difference in contrast attenuation of hepatocellular carcinoma (HCC) compared to background liver parenchyma resp.
- Conditions
- Contrast Media, Computed Tomography, Imaging, Pancreatic Cancer
- Trial name
- NCT04813432
- Testing
- Computed Tomography of the Abdomen
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Karolinska Institutet
Chronic Kidney Disease, End Stage Renal Disease
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
The purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the…
- Conditions
- Chronic Kidney Disease, End Stage Renal Disease, Coronary Artery Calcification, Vascular Calcification
- Trial name
- NCT00379899
- Testing
- cinacalcet
- Volunteers
- 360 people
- Sponsor
- Amgen
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.